Xpert® C. difficile BT
Detection of Clostridioides difficile in Around 45 Minutes
Inicie sesión o cree una cuenta de MyCepheid para añadir artículos a la cesta 
Número de ensayos
product image
10 Pruebas
GXCDIFFBT-CE-10
Cant.
Precio por unidad
Subtotal
USD
El producto no está disponible para la compra en su región.
Dispositivos de recogida
product image
Collection Device (Pack of 50)
900-0370
Cant.
Precio por unidad
Subtotal
USD
El producto no está disponible para la compra en su región.
product image
Single Use Disposable Swab (Pack of 120)
SDPS-120
Cant.
Precio por unidad
Subtotal
USD
El producto no está disponible para la compra en su región.
Total
{{currency}}
0
Error al añadir los artículos a la cesta. Si este error persiste, póngase en contacto con Soporte digital.

The Need

  • Clostridioides difficile (C. difficile) is amongst the most frequently reported micro-organisms in healthcare associated infections in Europe1
  • It is associated with an increase in length of hospital stay, high morbidity and mortality resulting in both societal and financial burden2
  • Highly virulent (027-NAP1-BI) strains have caused outbreaks of severe diseasae in Europe and North America and are often resistant to fluoroquinolones3
  • Although the accurate and rapid diagnosis of C. difficile is essential for effective and timely treatment, this remains an unmet clinical need4
1 Viprey, V. F., Granata, G., & Vendrik, K. (n.d.). European survey on the current surveillance practices, management ... https://www.journalofhospitalinfection.com/article/S0195-6701(22)00365-6/fulltext.
2 Tschudin-Sutter S, et al. Guidance document for prevention of C. difficile infection in acute healthcare settings. Clin Microbiol Infect 2018;24:1051
3 Markovska, R et al. Clostridioides difficile, a new suberbug, Microorganisms 2023, 11, 845. https://doi.org/10.3390/microorganisms11040845
4 Bai Y, Hao Y, Song Z, Chu W, Jin Y, Wang Y. Evaluation of the Cepheid Xpert C. difficile diagnostic assay: an update meta-analysis. Braz J Microbiol. 2021 Dec;52(4):1937-1949.

The Solution

  • Xpert C. difficile BT provides detection and differentiation of Clostridioides difficile & the epidemic    027 strain, with a callout for binary toxin, in 43 minutes from unformed stool specimens
  • Rapid detection and differentiation of Clostridioides difficile & the epidemic 027 strain optimizes patient management decisions, enables timely and appropriate treatment, and supports infection control and outbreak prevention measures4
4 Bai Y, Hao Y, Song Z, Chu W, Jin Y, Wang Y. Evaluation of the Cepheid Xpert C. difficile diagnostic assay: an update meta-analysis. Braz J Microbiol. 2021 Dec;52(4):1937-1949.

The Impact

  • Rapid and accurate detection of toxigenic C. difficile is essential to diagnose CDI to implement optimized therapy and bed management and to help prevent transmission and outbreaks:
    45% reduced empiric therapy5
    48% reduced isolation days6
5 Peppard W, et al. Implementation of polymerase chain reaction to rule out C. difficile infection is associated with reduced empiric antibiotic duration of therapy. Hosp Pharm. 2014 Jul;49(7):639-43.
6 Casari E, et al. Reducing rates of Clostridium difficile infection by switching to a stand-alone NAAT with clear sampling criteria. Antimicrob Resist Infect Control. 2018 Mar;7(40).